Clinical Trial

In just over two years, a Vanderbilt-Neumora collaboration has led to the Phase 1 clinical trial of a treatment for schizophrenia spectrum disorders, which affect 3.7 million adults in the United States. This is the third chemical compound discovered at the Warren Center for Neuroscience Drug Discovery to reach Phase 1 clinical trials.     Read More

In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11 with moderate-to-severe asthma, offering a new option to these patients. Read More

An automated system using keyword searches can help identify candidates for clinical trials on adverse drug reactions. Read More

Diabetes drugs known as GLP-1 receptor agonists, such as exenatide (Byetta), are a promising and safe treatment for a rare form of obesity. Read More

An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial. Read More

A drug combination effectively killed aggressive blood cancers in cell and animal models; now it’s being tested in patients. Read More

A new study published in Neurology reports the drug trofinetide has proven safe and effective in treating core symptoms of Rett syndrome in female children and adolescents. Read More

The rates of myopia, or nearsightedness, in pediatric patients have steadily increased with little to no change in treatment, which, for decades, has had ophthalmologists and optometrists turning to corrective lenses for improved vision. Read More

The growing list of patients needing liver transplants continues to outpace the number of available donor organs, but a new preservation and transport device for donor livers could possibly make a big difference. Read More

Vanderbilt researcher Tonia Rex, Ph.D., is accustomed to performing studies in her lab with a goal of translating the findings into better diagnoses and treatment tools for the visually impaired. Read More

Vanderbilt-Ingram Cancer Center (VICC) has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer. Read More

Vanderbilt University Medical Center (VUMC) is studying the safety of a possible treatment for diabetic kidney disease that would delay or prevent the need for kidney replacement such as dialysis. Read More

Based on findings from Vanderbilt investigators and others, clinical trials of estrogen inhibition for pulmonary arterial hypertension have recently been approved and funded by the National Institutes of Health. Read More

Vanderbilt University Medical Center is currently enrolling women to participate in a study looking at the drug Montelukast to treat interstitial cystitis/bladder pain syndrome (IC/BPS). Read More

Eighteen-year-old Grace Long had just been accepted at the renowned United States Naval Academy, with plans to become a nuclear engineering officer. Then, she learned she had type 1 diabetes, an immediate disqualifier for military service. Read More

Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has been selected to lead a clinical research trial of combination therapy using two targeted drugs for the treatment of a specific form of lung cancer. Read More

Vanderbilt University Medical Center (VUMC) is the first in the state to enroll patients in a clinical trial testing the effectiveness of the newest implantable device used to reduce stroke risk in patients with non-valvular atrial fibrillation (AF), the most common form of arrhythmia. Read More

In 2011, doctors at the Vanderbilt Heart and Vascular Institute performed the state’s first transcatheter valve-replacement (TAVR) procedure for high-risk patients suffering from aortic stenosis, the most common valvular heart disease in the United States. Read More

Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis. Read More

This month an international HIV prevention trial was launched that is testing the infection-preventing prowess of a monoclonal antibody called VRCO1. Read More